Survival benefit of remdesivir in hospitalized COVID-19 patients with high SARS-CoV-2 viral loads and low-grade systemic inflammation.
Sergio PadillaKristina PolotskayaMarta Fernández-GonzálezNieves Gonzalo-JiménezAlba de la RicaJosé Alberto GarcíaJavier García-AbellánPaula MascarellFelix GutiérrezMar MasiáPublished in: The Journal of antimicrobial chemotherapy (2022)
The benefits of remdesivir administered with dexamethasone and tocilizumab in hospitalized COVID-19 patients differ depending on Ct and CRP. Remdesivir decreases the risk of mortality and need for IMV in patients with high viral loads and low-grade systemic inflammation.
Keyphrases
- low grade
- sars cov
- high grade
- respiratory syndrome coronavirus
- rheumatoid arthritis
- computed tomography
- low dose
- cardiovascular events
- juvenile idiopathic arthritis
- magnetic resonance imaging
- cardiovascular disease
- type diabetes
- contrast enhanced
- magnetic resonance
- positron emission tomography
- rheumatoid arthritis patients